Anc80 Resources

Anc80: a novel AAV capsid

Odylia has exclusive rights to the Anc80 AAV vector for use in developing gene therapies to treat rare and ultra-rare retinal diseases. Anc80 is an ancestral adeno-associated virus, which was discovered in 2015 in the lab of Luk H. Vandenberghe, at Massachusetts Eye and Ear. Dr. Vandenberghe’s laboratory discovered Anc80 through their efforts to identify safer, more effective viral vector-based delivery systems. Anc80 is predicted to be the ancestor of the broadly utilized AAV1, AAV2, AAV8, and AAV9, and can effectively transduce the retina, central nervous system, muscle, liver, heart muscle, and cells of the inner ear to name a few.

Anc80 Publications

In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector

A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear

Gene Therapy Restores Auditory and Vestibular Function in a Mouse Model of Usher Syndrome Type 1c

Cochlear gene therapy with ancestral AAV in adult mice: complete transduction of inner hair cells without cochlear dysfunction

Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting

Synthetic Adeno-Associated Viral Vector Efficiently Targets Mouse and Nonhuman Primate Retina In Vivo

Delivery of Adeno-Associated Virus Vectors in Adult Mammalian Inner-Ear Cell Subtypes Without Auditory Dysfunction

Efficient Gene Transfer to Kidney Mesenchymal Cells Using a Synthetic Adeno-Associated Viral Vector